Following promising data presented at today’s poster session, results from RELIEF #Behcets study show #apremilast leads to ↓ rates of new/recurrent/worsening oral ulcers, skin lesions & #arthritis compared to placebo at 12wks.
Abs#0512 #ACR20 @RheumNow

https://t.co/O1dstY5WlL https://t.co/0djnUGw0Hg